
LAVA Therapeutics NV
NASDAQ:LVTX

LAVA Therapeutics NV
Cost of Revenue
LAVA Therapeutics NV
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
LAVA Therapeutics NV
NASDAQ:LVTX
|
Cost of Revenue
-$3.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Pharming Group NV
AEX:PHARM
|
Cost of Revenue
-$35.4m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-29%
|
|
![]() |
ProQR Therapeutics NV
NASDAQ:PRQR
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Uniqure NV
NASDAQ:QURE
|
Cost of Revenue
-$18.3m
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
argenx SE
XBRU:ARGX
|
Cost of Revenue
-$227.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Merus NV
NASDAQ:MRUS
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
LAVA Therapeutics NV
Glance View
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

See Also
What is LAVA Therapeutics NV's Cost of Revenue?
Cost of Revenue
-3.5m
USD
Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Cost of Revenue amounts to -3.5m USD.